The Cost Effectiveness of LAA Exclusion. Review uri icon

Overview

abstract

  • Left atrial appendage (LAA) exclusion strategies are increasingly utilized for stroke prevention in lieu of oral anticoagulants. Reductions in bleeding risk and long-term compliance issues bundled with comparable stroke prevention benefits have made these interventions increasingly attractive. Unfortunately, healthcare funding remains limited. Comparative cost economic analyses are therefore critical in optimizing resource allocation. In this review we seek to discourse the cost economics analysis of LAA exclusion over available therapeutic alternatives (warfarin and the new oral anticoagulants (NOACs)). .

publication date

  • February 29, 2016

Identity

PubMed Central ID

  • PMC5089495

Digital Object Identifier (DOI)

  • 10.4022/jafib.1374

PubMed ID

  • 27909482

Additional Document Info

volume

  • 8

issue

  • 5